We hypothesized that defective clearance of materials present in the airways contributes to the presentation of PAP in LPI patients, and treating the LPI cells with SP-D and GM-CSF could enhance the innate immune potential of these cells. The gene discussed is CSF2; the disease is pulmonary alveolar proteinosis.